Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTIPD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)
See Screening Protocol LUNGMAP
Effective February 22, 2019 at 2:00 pm Pacific Time, Cohort 1, the acquired resistance cohort of substudy S1400F will be temporarily closed to accrual in order to allow data to mature to conduct the planned interim analysis. Please note that Cohort 2, the primary resistance cohort, remains open to accrual.